



MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

October 28, 2021 2:00 PM EDT

Nkarta to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates

SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

Under the terms of the agreement, Nkarta obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.

The Nkarta approach maximizes the therapeutic effect of allogeneic NK cells through robust expansion, enhanced targeting and extended persistence resulting in potent immune cells that enable a sustained anti-cancer immune-mediated attack.

"Broad access to the most powerful and promising enabling technologies is critical to our success and the innovation of next-generation NK cell therapies for cancer patients," said **Paul J. Hastings, Nkarta's President and CEO**. "MaxCyte's electroporation technology leads the field and we're excited to leverage the advantages of their transfection technology with our integrated cell engineering platform."

Doug Doerfler, President and CEO of MaxCyte, said: "We are proud to support Nkarta's pioneering platform that has the potential to boost the body's immune response to fight cancer. Our team is thrilled to be working with a leader in developing novel products leveraging the unique power of NK cells for the treatment of patients with cancer."

MaxCyte's ExPERT™ instrument portfolio is the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Nkarta, Inc. is MaxCyte's 15th SPL adding to three MaxCyte partnerships year-to-date, which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary relate processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group
David Deuchler, CFA

+1 415-937-5400
ir@maxcyte.com

US Media Relations

Laura Morgan
Sam Brown Healthcare Communications

+1 951-333-9110
lauramorgan@sambrown.com

Nominated Adviser and Joint Corporate Broker

Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh

+44 (0)203 709 5700
maxcyte@consilium-comms.com